Current drug development portfolio for antimalarial therapies

Giancarlo Biagini; Paul M. O'Neill; Patrick G. Bray; Steve Ward

doi:10.1016/j.coph.2005.05.004

Current drug development portfolio for antimalarial therapies

Giancarlo Biagini, Paul M. O'Neill, Patrick G. Bray, Steve Ward

Tropical Disease Biology

Research output: Contribution to journal › Review article › peer-review

50 Citations (Scopus)

Abstract

In response to the emergence of parasite drug resistance to currently deployed antimalarials, the scientific community, in partnership with the pharmaceutical industry and public organizations, has fashioned an antimalarial drug development portfolio for the sustained development and registration of safe, effective and cheap antimalarial medicines. The management of this portfolio is being driven by MMV (Medicines for Malaria Venture), with a number of projects recently reaching the clinical end of this drug development pipeline.

Original language	English
Pages (from-to)	473-478
Number of pages	6
Journal	Current Opinion in Pharmacology
Volume	5
Issue number	5 SPEC.ISS.
DOIs	https://doi.org/10.1016/j.coph.2005.05.004
Publication status	Published - 1 Oct 2005

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1016/j.coph.2005.05.004

Cite this

@article{999ad201835647108ef7f12d8a9115be,

title = "Current drug development portfolio for antimalarial therapies",

abstract = "In response to the emergence of parasite drug resistance to currently deployed antimalarials, the scientific community, in partnership with the pharmaceutical industry and public organizations, has fashioned an antimalarial drug development portfolio for the sustained development and registration of safe, effective and cheap antimalarial medicines. The management of this portfolio is being driven by MMV (Medicines for Malaria Venture), with a number of projects recently reaching the clinical end of this drug development pipeline.",

author = "Giancarlo Biagini and O'Neill, \{Paul M.\} and Bray, \{Patrick G.\} and Steve Ward",

year = "2005",

month = oct,

day = "1",

doi = "10.1016/j.coph.2005.05.004",

language = "English",

volume = "5",

pages = "473--478",

journal = "Current Opinion in Pharmacology",

issn = "1471-4892",

publisher = "Elsevier Ltd",

number = "5 SPEC.ISS.",

}

TY - JOUR

T1 - Current drug development portfolio for antimalarial therapies

AU - Biagini, Giancarlo

AU - O'Neill, Paul M.

AU - Bray, Patrick G.

AU - Ward, Steve

PY - 2005/10/1

Y1 - 2005/10/1

N2 - In response to the emergence of parasite drug resistance to currently deployed antimalarials, the scientific community, in partnership with the pharmaceutical industry and public organizations, has fashioned an antimalarial drug development portfolio for the sustained development and registration of safe, effective and cheap antimalarial medicines. The management of this portfolio is being driven by MMV (Medicines for Malaria Venture), with a number of projects recently reaching the clinical end of this drug development pipeline.

AB - In response to the emergence of parasite drug resistance to currently deployed antimalarials, the scientific community, in partnership with the pharmaceutical industry and public organizations, has fashioned an antimalarial drug development portfolio for the sustained development and registration of safe, effective and cheap antimalarial medicines. The management of this portfolio is being driven by MMV (Medicines for Malaria Venture), with a number of projects recently reaching the clinical end of this drug development pipeline.

U2 - 10.1016/j.coph.2005.05.004

DO - 10.1016/j.coph.2005.05.004

M3 - Review article

SN - 1471-4892

VL - 5

SP - 473

EP - 478

JO - Current Opinion in Pharmacology

JF - Current Opinion in Pharmacology

IS - 5 SPEC.ISS.

ER -

Current drug development portfolio for antimalarial therapies

Abstract

UN SDGs

Access to Document

Fingerprint

Cite this